The Company is pleased to announce the publication of a Medtech Innovation Briefing (MIB) on the PromarkerD predictive test for diabetic kidney disease by the National Institute for Health and Care Excellence (NICE) in the United Kingdom. NICE is an independent organisation established by the UK Government to provide national guidance and advice to it on medical treatments.
Medtech Innovation Briefing, known as NICE advice, reports that PromarkerD is effective at predicting renal function decline in people with type 2 diabetes.
Outcome is a major milestone towards reimbursement and the broad adoption of PromarkerD in the UK Company will now target the inclusion of the test in the NICE guidelines.
